Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Osteoporos Int. 2021 Aug 12;33(1):239–250. doi: 10.1007/s00198-021-06065-4

Table 3.

Incidence of adverse events by body system and group

Body System and Preferred Term* TPTD Placebo Total
N (%) N (%) N (%)
Number of Patients 18 17 35
Number of Events 35 18 53
Number of Patients with Events 12 (67) 10 (59) 22 (63)
Head
Dizziness/faintness 1 (3) 1 (2)
Nose/Throat
Difficulty swallowing 1 (6)
Flu/Upper Respiratory Problems 1 (3) 1(2)
Sinus Condition 1 (3) 2 (11) 3 (6)
Chest
Shortness of breath 1 (6) 1 (2)
Gastrointestinal
Nausea 1 (3) 2 (11) 3 (6)
Vomiting 1 (3) 1 (2)
Diarrhea 1 (3) 1 (6) 2 (4)
Appetite decrease 1 (3) 1 (2)
Genitourinary
Painful urination 1 (3) 1 (2)
Difficulty urinating 1 (3) 1 (2)
Increased frequency of urination 2 (6) 2 (4)
Musculoskeletal
Muscle/bone/joint pain/condition 7 (20) 2(11) 9 (17)
Edema 2 (6) 1 (6) 3 (6)
Psychological/Behavioral
Tiredness/fatigue 2 (6) 2 (4)
Other
Accidental injury 5 (14) 3 (17) 8 (15)
Medical or surgical procedure 3 (17) 3 (6)
Not Otherwise Listed (or Unknown) 8 (23) 3 (17) 11 (21)